The natural history of drug-induced liver injury

Seminars in Liver Disease

Volumn 29, Issue 4, 2009, Pages 357-363

  Björnsson, Einar ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute liver failure; Eosinophilia; Hepatic necrosis; Hy's rule; Liver transplantation

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; AZATHIOPRINE; BENTAZEPAM; BILIRUBIN; CARBAMAZEPINE; CHLORPROMAZINE; COTRIMOXAZOLE; DICLOFENAC; DISULFIRAM; ERYTHROMYCIN; FLUCLOXACILLIN; HALOTHANE; ISONIAZID; METHOTREXATE; NITROFURANTOIN; PARACETAMOL; PHENYTOIN; RAMIPRIL; SULINDAC; VALPROIC ACID;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BRAIN DISEASE; CELL INFILTRATION; CHOLESTASIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; EOSINOPHILIA; FATALITY; GENDER; HOSPITALIZATION; HUMAN; JAUNDICE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; LIVER TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REYE SYNDROME; RISK FACTOR; SPAIN; SWEDEN; UNITED STATES;

ACUTE DISEASE; BLOOD COAGULATION DISORDERS; DISEASE PROGRESSION; DRUG-INDUCED LIVER INJURY; DRUG-INDUCED LIVER INJURY, CHRONIC; HEALTH STATUS INDICATORS; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70449086055     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1240004     Document Type: Article

References (49)

1. Zimmerman H. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA Lippincott, Williams & Wilkins 1999
2. Bjrnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005 42 (2) 481-489
3. Ostapowicz G, Fontana R J., Schidt F V. et al, U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002 137 (12) 947-954
4. Wei G, Bergquist A, Broom U et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007 262 (3) 393-401
5. Larson A M., Polson J, Fontana R J. et al, Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005 42 (6) 1364-1372
6. Chun L J., Tong M J., Busuttil R W., Hiatt J R. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009 43 (4) 342-349
7. Lee W M., Hynan L S., Rossaro L et al. Intravenous N -acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009 137 856-864
8. Bacardi R, Report from the European Association for the Study of the Liver (EASL). Randomised trial of steroid therapy in acute liver failure. Gut 1979 20 (7) 620-623
9. Dechene A, Treichel U, Gerken G et al. Effectiveness of a steroid and ursodeoxycholic acid combination therapy with drug-induced subacute liver failure. Hepatology 2005 42 358A
10. Fontana R J. Acute liver failure due to drugs. Semin Liver Dis 2008 28 (2) 175-187
11. Ibez L, Prez E, Vidal X, Laporte J R., Grup d'Estudi Multicnteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002 37 (5) 592-600
12. Chalasani N, Fontana R J., Bonkovsky H L. et al, Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008 135 (6) 1924-1934, 1934, e1e4
13. Bjrnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007 25 (12) 1411-1421
14. Andrade R J., Lucena M I., Fernndez M C. et al, Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005 129 (2) 512-521
15. Ohmori S, Shiraki K, Inoue H et al. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepatogastroenterology 2003 50 (53) 1531-1534
16. Gitlin N. The serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase ratio as a prognostic index in severe acute viral hepatitis. Am J Gastroenterol 1982 77 2-4
17. El-Serag H B., Everhart J E. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002 122 (7) 1822-1828
18. Wang T, Shankar K, Ronis M J., Mehendale H M. Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes. Crit Rev Toxicol 2007 37 (5) 413-459
19. Bjrnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009 50 (3) 511-517
20. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002 22 (2) 145-155
21. Lucena M I., Andrade R J., Kaplowitz N et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009 49 2001-2009
22. de Abajo F J., Montero D, Madurga M, Garca Rodrguez L A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004 58 (1) 71-80
23. Aithal P G., Day C P. The natural history of histologically proved drug induced liver disease. Gut 1999 44 (5) 731-735
24. Andrade R J., Lucena M I., Kaplowitz N et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006 44 (6) 1581-1588
25. Schmidt L E., Dalhoff K, Poulsen H E. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002 35 (4) 876-882
26. Cross F S., Long M W., Banner A S., Snider D E. Jr. Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial. Am Rev Respir Dis 1980 122 (2) 349-353
27. Pande J N., Singh S P., Khilnani G C., Khilnani S, Tandon R K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996 51 (2) 132-136
28. Fountain F F., Tolley E, Chrisman C R., Self T H. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005 128 (1) 116-123
29. Dssing M, Wilcke J T., Askgaard D S., Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996 77 (4) 335-340
30. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996 9 (10) 2026-2030
31. Danan G, Benichou C. Causality assessment of adverse reactions to drugsI. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993 46 (11) 1323-1330
32. Bjrnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006 44 (4) 791-797
33. Black M, Mitchell J R., Zimmerman H J., Ishak K G., Epler G R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975 69 (2) 289-302
34. Benjamin S B., Goodman Z D., Ishak K G., Zimmerman H J., Irey N S. The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases. Hepatology 1985 5 (6) 1163-1171
35. Lucena M I., Camargo R, Andrade R J., Perez-Sanchez C J., Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001 33 (1) 123-130
36. Pachkoria K, Lucena M I., Crespo E et al, Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatas Asociadas a Medicamentos (GEHAM)). Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 2008 49 (1) 107-114
37. Lampinen M, Rnnblom A, Amin K et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005 54 (12) 1714-1720
38. Bethwaite P B., Holloway L J., Yeong M L., Thornton A. Effect of tumour associated tissue eosinophilia on survival of women with stage IB carcinoma of the uterine cervix. J Clin Pathol 1993 46 (11) 1016-1020
39. Bjrnsson E, Kalaitzakis E, Av Klinteberg V, Alem N, Olsson R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007 26 (1) 79-85
40. Stricker B H., Blok A P., Claas F H., Van Parys G E., Desmet V J. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988 8 (3) 599-606
41. Olsson R, Wiholm B E., Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992 15 (1-2) 154-161
42. Oikawa H, Maesawa C, Sato R et al. Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report. World J Gastroenterol 2005 11 (34) 5394-5397
43. Whiting-O'Keefe Q E., Fye K H., Sack K D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991 90 (6) 711-716
44. Russell R I., Allan J G., Patrick R. Active chronic hepatitis after chlorpromazine ingestion. BMJ 1973 1 (5854) 655-656
45. Yeung E, Wong F S., Wanless I R. et al. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 2003 127 (11) 1493-1497
46. Mazeika P K., Ford M J. Chronic active hepatitis associated with diclofenac sodium therapy. Br J Clin Pract 1989 43 (3) 125-126
47. Bnichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990 11 (2) 272-276
48. Garcia-Munoz B, Lopez-Ortega S, Borraz Y et al. The natural history of idiosyncratic drug-induced liver injury (DILI): follow-up in a cohort of patients identified in a single tertiary care centre. J Hepatol 2008 48 S336
49. Fontana R J., Watkins P B., Bonkovsky H L. et al, DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009 32 (1) 55-68